×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IPHA – innate pharma s.a. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IPHA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
01:22 am
ipha
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/20
01:00 am
ipha
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
12/11
09:59 pm
ipha
3 Promising Penny Stocks With Market Caps Under US$300M [Yahoo! Finance]
Medium
Report
3 Promising Penny Stocks With Market Caps Under US$300M [Yahoo! Finance]
12/9
08:11 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
12/9
01:00 am
ipha
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
High
Report
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
12/6
01:00 am
ipha
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Low
Report
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
12/3
01:00 am
ipha
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Medium
Report
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
11/20
01:00 am
ipha
Innate Pharma Releases Its 2025 Financial Calendar
High
Report
Innate Pharma Releases Its 2025 Financial Calendar
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/24
Innate Pharma Files Its 2019 Universal Registration Document (Document d’enregistrement universel) and Its 2019 Annual Report on Form 20-F
15.1%
1/2 The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia 13.4%
4/14 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders 6.8%
3/10 Innate Pharma reports FY results [Seeking Alpha] 6.5%
3/3 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.8%
1/31 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm 3.0%
2/26 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.3%
11/6 Innate Pharma announces preclinical data presentations at SITC 2019 2.2%
11/7 Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting 2.2%
1/13 French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides 2.0%
1/2 The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia 13.4%
4/14 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders 6.8%
3/10 Innate Pharma reports FY results [Seeking Alpha] 6.5%
3/3 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.8%
1/31 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm 3.0%
2/26 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.3%
11/6 Innate Pharma announces preclinical data presentations at SITC 2019 2.2%
11/7 Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting 2.2%
1/13 French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides 2.0%
TOP News Decliners
3/14
Innate Pharma SA (IPHYF) CEO Mondher Mahjoubi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-12.6%
4/23 Innate Pharma S.A. (NASDAQ: IPHA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.8%
1/9 Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial -10.0%
1/2 Innate Pharma's stock rallies 23% on leukemia drug submission in Europe [MarketWatch] -7.6%
12/13 Innate Pharma Provides Update on Lacutamab TELLOMAK Trial -4.4%
2/14 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.3%
1/29 EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA -3.3%
11/13 Innate Pharma third quarter 2019 report -3.1%
12/8 Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019 -3.1%
10/21 Innate Pharma Announces Closing of Global Offering -3.1%
4/23 Innate Pharma S.A. (NASDAQ: IPHA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.8%
1/9 Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial -10.0%
1/2 Innate Pharma's stock rallies 23% on leukemia drug submission in Europe [MarketWatch] -7.6%
12/13 Innate Pharma Provides Update on Lacutamab TELLOMAK Trial -4.4%
2/14 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.3%
1/29 EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA -3.3%
11/13 Innate Pharma third quarter 2019 report -3.1%
12/8 Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019 -3.1%
10/21 Innate Pharma Announces Closing of Global Offering -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: